Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
Prostate cancer is one of the most heritable cancers in men, and recent genome-wide association studies have revealed numerous genetic variants associated with disease. The risk variants identified using case-control designs that compared unaffected individuals with all types of patients with prostate cancer show little or no ability to discriminate between indolent and fatal forms of this disease. This suggests different genetic components are involved in the initiation as compared with the prognosis of prostate cancer. Future studies contrasting patients with more and less aggressive disease, and exploring association with disease progression and prognosis, should be more effective in detecting genetic risk factors for prostate cancer outcome.
Wiklund
Fredrik
F
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Bos 281, 171 77 Stockholm, Sweden. ross.hopkins@biomedcentral.com.